Blondin Bioscience Information

Blondin Bioscience is a team of expert scientists and business professionals driven to dramatically impact how cancer is treated, decreasing the cancer burden for patients, physicians, and insurance companies. Our current primary product for cancer immunology is a best-in-class TLR9 antibody, which is currently available for purchase. Under development is our cancer molecular diagnostic assay, FACT, which capitalizes on proprietary intellectual property exclusively by Blondin Bioscience. FACT is a blood test which measures a nucleic acid biomarker released from dying cancer cells. It can be used to assess the efficacy of cancer treatment within a few days as opposed to two months with routine radiology. By collapsing the amount of time required for treatment efficacy assessment, Blondin Bioscience will contribute to reducing the overall cancer burden for patients. Speeding the time to knowledge will reduce the emotional expenditure, financial burden, potential side effects from ineffective drugs, and perhaps most importantly, the time required to find the optimal treatment protocol. In short, we hope to save lives.